The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00167882

Recruitment Status : Completed

First Posted : September 14, 2005

Last Update Posted : September 11, 2006

Sponsor:

Information provided by:

VU University Medical Center

Study Description

Brief Summary:

The purpose of this study is to determine the influence of different 5-aminosalicylate concentrations on the metabolism of azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.

Condition or disease	Intervention/treatment	Phase
Crohn's Disease Ulcerative Colitis Inflammatory Bowel Disease	Drug: 5-aminosalicylate (Pentasa, Ferring)	Phase 4

Detailed Description:

Background:

The concomitant use of 5-aminosalicylates (5ASA) next to azathioprine (AZA) or 6-mercaptopurine (6MP) in the treatment of inflammatory bowel disease (IBD) may lead to an increased effectiveness of therapy as higher levels of the active metabolite of AZA/6MP (6-thioguaninenucleotides (6TGNs) are measured.

Objectives:

To determine the influence of 5-ASA compounds and its metabolites on the metabolites of AZA/6MP (6TGNs + 6-methylmercaptopurine (6MMP).

Methods:

Patients with quiescent disease under AZA/6MP therapy are eligible. Patients will receive three succeeding regimes (5ASA 2 gram/5ASA 4 gram/ no 5ASA) of 4 weeks next to the standard AZA/6MP therapy. At the start and at the end of every regime 5ASA and its major metabolite (N-acetyl-5ASA) will be determined in serum next to the measurement of 6TGNs and 6MMP in erythrocytes. The safety will monitored by standard laboratory parameters every four weeks.

Population:

Patients with IBD in remission and unchanged AZA/6MP dosages for at least 4 weeks.

Medication:

5ASA (Pentasa ® granules; Ferring) will be administered orally in dosages of 2 or 4 grams daily for a period of 4 weeks.

Endpoints:

The rise or decrease in 6TGNs and 6MMP during the different 5ASA regimes. The evaluation of the safety of co-administrating 5ASA next to AZA/6MP.

Risks:

Side effects of 5ASA use are limited and well known. Some case reports have described the potential risk of developing a myelodepression when AZA/6MP and 5ASA are given together due to the rise in 6TGNs. However, in daily practice both drugs are administered together frequently. The risks of the frequent blood draws are minimal and usually self-limiting (haematoma).

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Enrollment :	24 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	Single
Primary Purpose:	Treatment
Study Start Date :	July 2005
Study Completion Date :	August 2006

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Thiopurine S-methyltransferase deficiency Ulcerative colitis Crohn disease

Drug Information available for: Mesalamine Mesalamine hydrochloride

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

To determine the influence of 5-ASA compounds and its metabolites on the 6-TGN level during steady state AZA or 6-MP dosages

Secondary Outcome Measures :

To determine the influence of 5-ASA compounds and its metabolites on the 6-MMP level during steady state AZA or 6-MP dose
To determine the influence of 5-ASA compounds and its metabolites on the 6-TGMP, 6-TGDP and 6-TGTP levels during steady state AZA or 6-MP dosages
To evaluate the safety of co-administrating 5-ASA and AZA or 6-MP in IBD patients

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adult patients, aged between 18 - 70 years
Informed consent
Diagnosis of CD or UC for at least 6 months (histological and endoscopically confirmed)
Steady state AZA of 6-MP use (an unchanged thiopurine regime for at least 4 weeks)
Normal liver and kidney function (ALAT / AP / creatinin < 2 x upper normal limit)
Quiescent disease (HBI score ≤ 4 for CD or modified TLWI score ≤ 4 for UC)

Exclusion Criteria:

Bone marrow suppression (platelets / leucocytes < 1 x lower normal level)
Presence of active infection (fever and CRP > 1 x upper normal limit)
Anemia (hemoglobin < 6 mmol)
Known duodenal Crohn's disease interfering significantly with resorptive area
Small bowel surgery interfering significantly with resorptive area
Known intolerance to 5-ASA compounds
Current use of 5-ASA compounds
Use of 5-ASA compounds within the last 30 days
Concomitant use of allopurinol, ACE-inhibitors or furosemide
Pregnancy, expected pregnancy or lactation within 6 months

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00167882

Locations

Layout table for location information

Netherlands
Maasland Hospital
Sittard, Netherlands

Sponsors and Collaborators

VU University Medical Center

Investigators

Layout table for investigator information

Principal Investigator:	K.H.N. de Boer, MD	VU University Medical Center

More Information

Publications:

Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004 Jun;26(3):311-8.

de Boer NK, de Graaf P, Wilhelm AJ, Mulder CJ, van Bodegraven AA. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment Pharmacol Ther. 2005 Sep 1;22(5):447-51.

Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005 Apr;37(4):282-97. Review.

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00167882
Other Study ID Numbers:	2005/28
First Posted:	September 14, 2005 Key Record Dates
Last Update Posted:	September 11, 2006
Last Verified:	August 2006

Keywords provided by VU University Medical Center:


Crohn's disease Ulcerative colitis Inflammatory bowel disease azathioprine	6-mercaptopurine 5-aminosalicylate metabolism

Additional relevant MeSH terms:

Layout table for MeSH terms

Crohn Disease Colitis Colitis, Ulcerative Intestinal Diseases Inflammatory Bowel Diseases Ulcer Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Colonic Diseases	Pathologic Processes Mesalamine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents

To Top